Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Minimed Group's revenue for the
three
months ended in Apr. 2026 was €716 Mil.
Its revenue for the trailing twelve months (TTM) ended in Apr. 2026 was €1,388 Mil.
Minimed Group's Revenue per Share for the
three
months ended in Apr. 2026 was €2.55.
Its Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 was €4.94.
During the past 12 months, the average Revenue per Share Growth Rate of Minimed Group was 25.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 14.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 4 years, Minimed Group's highest 3-Year average Revenue per Share Growth Rate was 14.80% per year. The lowest was 14.80% per year. And the median was 14.80% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Minimed Group Revenue Related Terms
Minimed Group Revenue Historical Data
* Premium members only.
The historical data trend for Minimed Group's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Minimed Group's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minimed Group Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Minimed Group's Revenue distribution charts can be found below:
* The bar in red indicates where Minimed Group's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,388 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minimed Group (STU:B8S) has a Revenue of €1,388 Mil as of Apr. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Minimed Group and its competitors.
Is Minimed Group's Revenue too high?
Minimed Group's current Revenue is €1,388 Mil. Overall, Minimed Group has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Minimed Group's Revenue compare to MMSI and NVST?
Minimed Group's Revenue of €1,388 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Minimed Group and its competitors. Minimed Group's current Revenue is €1,388 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minimed Group stock overvalued right now?
Minimed Group (STU:B8S) has a current Revenue of €1,388 Mil. The current Revenue is €1,388 Mil. Minimed Group's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Minimed Group (STU:B8S), the current Revenue is €1,388 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.
20GF Score
Get the complete analysis for STU:B8S
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:B8S has been successfully added to your 
